by University of Manitoba Non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) improves the colitis-related disease activity index (DAI) and macroscopic score. Credit: Bioelectronic Medicine (2024). DOI: 10.1186/s42234-024-00162-5 A simple, non-invasive treatment focused on the ears could one day provide relief for people with ulcerative colitis, a UM research study has found. The study, “Exploring the efficacy of transcutaneous...
Tag: <span>ulcerative colitis</span>
Post
First American Gastroenterological Association living guideline for moderate-to-severe ulcerative colitis
Subhead: Patients should start advanced therapies early rather than gradual step-up treatmentPeer-Reviewed Publication American Gastroenterological Association Bethesda, MD (Nov. 15, 2024) — The American Gastroenterological Association (AGA) has released a new clinical guideline on the pharmacological management of moderate-to-severe ulcerative colitis, published today in Gastroenterology. This guideline groups the 12 currently available advanced treatments based on...
Post
How ulcerative colitis can affect the eyes
Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD). The underlying inflammation of UC can lead to eye conditions such as scleritis and uveitis. Without treatment, some conditions may lead to vision loss. UC is a chronic condition that primarily affects the large intestine. It is a type of IBD, meaning that inflammation...
Post
MNT Investigates: Do ulcerative colitis treatments reduce the risk of heart attack?
Research has linked ulcerative colitis (UC) to an increased risk of heart disease, including heart attack and stroke. Some UC treatments may help reduce the risk of heart problems, though more research is necessary. UC refers to chronic inflammation in the inner lining of the large intestine. People with UC may also develop inflammation in...
Post
Front-line drug for ulcerative colitis found to have additional mechanism of action that until now remained elusive
JULY 23, 2024 by Delthia Ricks , Medical Xpress Response to vedolizumab is associated with loss of lymphoid aggregate size. (A) Representative hematoxylin and eosin staining of colonic biopsies from responder (R) and nonresponder (NR) patients with UC taken before and after VDZ therapy. Lymphoid aggregate (LA) border indicated with red line. Scale bars, 100...
Post
Low Serum Vitamin D Levels Linked to Ulcerative Colitis
Marilynn Larkin October 26, 2023 TOPLINE: Serum vitamin D levels are significantly lower and the prevalence of vitamin D deficiency is significantly higher in patients with ulcerative colitis (UC) compared with controls, although a causal relationship cannot be demonstrated. METHODOLOGY: TAKEAWAY: SOURCE: Yan Wang, PhD, Department of Gastroenterology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an,...
Post
FDA approves mirikizumab, a promising induction and maintenance therapy for ulcerative colitis
by The Mount Sinai Hospital Endoscopic image of a bowel section known as the sigmoid colon afflicted with ulcerative colitis. The internal surface of the colon is blotchy and broken in places. Credit: Samir/Wikipedia The U.S. Food and Drug Administration (FDA) approved mirikizumab, on October 26, 2023, a highly effective new treatment for ulcerative colitis (UC),...
Post
New AGA guideline recommends blood and stool tests for monitoring ulcerative colitis
AMERICAN GASTROENTEROLOGICAL ASSOCIATION Bethesda, MD (Feb. 21, 2023) — In new evidence-based guidelines, the American Gastroenterological Association (AGA) recommends non-invasive biomarkers as a first-line strategy for monitoring many patients with ulcerative colitis (UC). These guidelines were published today in Gastroenterology. The AGA guidelines outline use cases for three biomarkers that provide accurate insights into ulcerative colitis disease...
Post
In vivo self-assembled siRNA as a modality for combination therapy of ulcerative colitis
by Nanjing University School of Life Sciences Evaluation of the activity of TNF-α siRNA-encapsulating sEVs in an ex vivo model. a Schematic of the experimental design. Acute UC was induced in male BALB/c mice by replacing their drinking water with a 2.5% DSS solution for 7 days. DSS mice were intravenously injected with 5 mg/kg CMV-scrR...
Post
Quicker Remission With Tofacitinib vs Vedolizumab in Ulcerative Colitis: Study
Liam Davenport July 11, 2022 When anti–tumor necrosis factor-alpha (anti-TNF) treatment fails to achieve remission for patients with ulcerative colitis (UC), tofacitinib (Xeljanz) appears more effective sooner than vedolizumab (Entyvio), suggests a Dutch registry study. Data on nearly 150 patients with UC who had already undergone treatment with anti-TNF drugs showed that combined clinical and biochemical remission was about five times more likely...